HKAPI Welcomes Everest Medicines as First Full Member After Membership Restructuring
We are pleased to announce that Everest Medicines has been accepted as a full member of the Hong Kong Association of the Pharmaceutical Industry (HKAPI).
Everest Medicines is the first company to join as a full member of the HKAPI following the recent restructuring of our membership categories. This milestone underscores the Association’s continued efforts to strengthen its representation of the pharmaceutical industry in Hong Kong.
Everest Medicines is a Hong Kong-listed (HKEX 1952.HK) biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative pharmaceutical products and vaccines. With its diverse pipeline and capabilities, Everest Medicines is well-positioned to contribute significantly to advancing the pharmaceutical industry in the region.
We welcome Everest Medicines as a full member of the HKAPI and look forward to their active participation in shaping the future of our industry. This addition marks an important step in the HKAPI’s ongoing commitment to promoting the growth and success of the pharmaceutical sector in Hong Kong and beyond.
